FDA Approves Nemluvio (nemolizumab) for the Treatment of Adult Patients with Prurigo Nodularis

FDA approves Nemluvio (nemolizumab) for treating adult patients with prurigo nodularis, based on positive results from the phase III OLYMPIA trials, demonstrating significant improvements in itch and skin nodules.